Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Candesartan + HCTZ in Severe Hypertension
NCT01012479Phase 4Completed
- Sponsor
- Takeda
- Start
- Oct 2009
- Primary completion
- May 2010
- Modality
- Prodrugs/Conditional Activator Small Molecules
- Countries
- 2
01
Overview
Phase 4, open-label, single-arm trial of candesartan cilexetil in essential hypertension, sponsored by Takeda. Primary endpoints: Change from Baseline in Systolic Blood Pressure at 9 weeks and Change from Baseline in Diastolic Blood Pressure at 9 weeks. Started Oct 2009; status: completed.
02
Drugs
candesartan cilexetil
03
Conditions
essential hypertension
Beyond the preview
Go deeper on NCT01012479.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01012479.